Selected international publications of the last years. The founders and team members of immatics are shown in bold letters.
Selected recent literature published by immatics’ founders and employees. The founders and team members of immatics are shown in bold letters.
The following list shows literature in chronological order selected from over 300 publications in international scientific journals.
Walter S, Weinschenk T et al. 2012. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nature Medicine, published online: 29 July 2012. -/ link
Britten CM, Janetzki S, Butterfield LH, Ferrari G, Gouttefangeas C, Huber C, Kalos M, Levitsky HI, Maecker HT, Melief CJM, O Donnell-Tormey J, Odunsi K, Old LJ, Ottenhoff THM, Ottensmeier C, Pawelec G, Roederer M, Roep BO, Romero P, van der Burg SH, Walter S, Hoos A, Davis MM. 2012. T Cell Assays and MIATA: The Essential Minimum for Maximum Impact. Immunity, published online: 27 July 2012. -/ link
Dutoit V, Herold-Mende C, Hilf N, Schoor O, Beckhove P, Bucher J, Dorsch K, Flohr S, Fritsche J, Lewandrowski P, Lohr J, Rammensee HG, Stevanovic S, Trautwein C, Vass V, Walter S, Walker PR, Weinschenk T, Singh-Jasuja H, Dietrich PY. 2012. Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy. Brain, published online: 14 March 2012. -/ link
Copier J, Dalgleish AG, Britten CM, Finke LH, Gaudernack G, Gnjatic S, Kallen K, Kiessling R, Schuessler-Lenz M, Singh H, Talmadge J, Zwierzina H, Håkansson L. 2009. Improving the efficacy of cancer immunotherapy. Eur J Cancer 45, 1424-31. -/ link
Hipp MM, Hilf N, Walter S, Werth D, Brauer KM, Radsak MP, Weinschenk T, Singh-Jasuja H, Brossart P. 2008. Sorafenib but not sunitinib affects function of dendritic cells and induction of primary immune responses. Blood 111, 5610-20. -/ link
Britten CM, Gouttefangeas C, Welters MJP, Pawelec G, Koch S, Ottensmeier C, Mander A, Walter S, Paschen A, Müller-Berghaus J, Haas I, Mackensen A, Kollgaard T, thor Straten P, Schmitt M, Giannopoulos K, Maier R, Veelken H, Bertinetti C, Konur A, Huber C, Stevanovic S, Woelfel T, van der Burg SH. 2007. The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8+ T lymphocytes by structural and functional assays. Cancer Immunol Immunother. -/ link
Dengjel J, Nastke MD, Gouttefangeas C, Gitsioudis G, Schoor O, Altenberend F, Muller M, Kramer B, Missiou A, Sauter M, Hennenlotter J, Wernet D, Stenzl A, Rammensee HG, Klingel K, Stevanovic S. 2006. Unexpected abundance of HLA class II presented peptides in primary renal cell carcinomas. Clin Cancer Res. 12:4163-70. -/ link
Krüger T, Schoor O, Lemmel C, Kraemer B, Reichle C, Dengjel J, Weinschenk T, Muller M, Hennenlotter J, Stenzl A, Rammensee HG, Stevanovic S. 2005. Lessons to be learned from primary renal cell carcinomas: novel tumor antigens and HLA ligands for immunotherapy. Cancer Immunol Immunother. 54:826-36. -/ link
Singh-Jasuja H, Emmerich NP, Rammensee HG. 2004. The Tübingen approach: identification, selection and validation of tumor-associated HLA peptides for cancer therapy. Cancer Immunol Immunother 53:187-95. -/ link
Schmidt SM, Schag K, Muller MR, Weinschenk T, Appel S, Schoor O, Weck MM, Grunebach F, Kanz L, Stevanovic S, Rammensee HG, Brossart P. 2004. Induction of adipophilin-specific cytotoxic T lymphocytes using a novel HLA-A2-binding peptide that mediates tumor cell lysis. Cancer Res 64:1164-70. -/ link
Schag K, Schmidt SM, Muller MR, Weinschenk T, Appel S, Weck MM, Grunebach F, Stevanovic S, Rammensee HG, Brossart P. 2004. Identification of C-met oncogene as a broadly expressed tumor-associated antigen recognized by cytotoxic T-lymphocytes. Clin Cancer Res 10:3658-66. -/ link
Lemmel C, Weik S, Eberle U, Dengjel J, Kratt T, Becker HD, Rammensee HG, Stevanovic S. 2004. Differential quantitative analysis of MHC ligands by mass spectrometry using stable isotope labeling. Nat Biotechnol 22:450-4. -/ link
Walter S, Herrgen L, Schoor O, Jung G, Wernet D, Buhring HJ, Rammensee HG, Stevanovic S. 2003. Cutting edge: predetermined avidity of human CD8 Tcells expanded on calibrated MHC/anti-CD28-coated microspheres. J Immunol 171:4974-8. -/ link
Weinschenk T, Gouttefangeas C, Schirle M, Obermayr F, Walter S, Schoor O, KurekR, Loeser W, Bichler KH, Wernet D, Stevanovic S, Rammensee HG. 2002. Integrated functional genomics approach for the design of patient-individual antitumor vaccines. Cancer Res 62:5818-27. -/ link
Rammensee HG, Weinschenk T, Gouttefangeas C, Stevanovic S. 2002. Toward patient-specific tumor antigen selection for vaccination. Immunol Rev.188:164-76. -/ link
Schirle M, Keilholz W, Weber B, Gouttefangeas C, Dumrese T, Becker HD, Stevanovic S, Rammensee HG. 2000. Identification of tumor-associated MHC class I ligands by a novel T cell-independent approach. Eur J Immunol 30:2216-2225. -/ link
Brossart P, Heinrich KS, Stuhler G, Behnke L, Reichardt VL, Stevanovic S, Muhm A, Rammensee HG, Kanz L, Brugger W. 1999. Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumorantigen for broadly applicable vaccine therapies. Blood 93:4309-4317. -/ link